{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"condition":["Advanced colorectal cancer"],"disease":["Advanced Colorectal Cancer"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2624189"],"location":["Japan"],"study_start_month":["5"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan","description":"Primary outcome(s): To evaluate the correlation between the efficacy or safety and the genetic polymorphism in patients with cetuximab plus irinotecan or panitumumab plus irinotecan therapy.","dates":{"creation":"2013-05-15"},"accession":"2624189","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000008786"]}}